Comparing the current results to its competitors, Omniab Inc reported Revenue increase in the 1 quarter 2026 by 247.3 % year on year. The sales growth was above Omniab Inc 's competitors' average revenue growth of 13.22 %, achieved in the same quarter.
Omniab Inc 's Comment on Competition and Industry Peers
The company operates in the global market for technologies that support therapeutic antibody discovery and development. Its competitors vary in size, scope, and technology, including transgenic animal platforms, single-cell screening, and antibody engineering. Competitors employ diverse business models such as developing internal pipelines, financial investments, licensing, and instrument sales. The company faces competition from integrated contract research organizations utilizing traditional hybridoma, phage, and yeast display technologies, as well as fee-for-service contract research organizations using legacy methods. Specific competitors include Nona Biosciences, Leveragen, Inc., Regeneron Pharmaceuticals, Inc., and Twist Bioscience Corporation in antibody discovery; AbCellera Biologics Inc., Bruker Corporation, DPBIO, Inc., Sartorius AG, and Fluidic Sciences Ltd in single-cell screening; and Charles River Labs Inc., Evotec SE, Metrion Biosciences Ltd., and WuXi AppTec in ion channel drug discovery.
June 3, 2024
OmniAb, Inc., a biotechnology company based in Emeryville, California, has recently made significant breakthroughs in the field of antibody engineering. Through the publication of a scientific paper in the Journal of Immunology, the company has demonstrated that chickens can be genetically modified to produce functional heavy chain-only single-domain antibodies (sdAbs). This innovation has the potential to revolutionize the production of antibodies, as sdAbs are known for their small size, robustness, and modular properties. Additionally, at the 20th Annual PEGS Boston Summit, OmniAb presented xPloration, a high-throughput single B-cell screening platform that utilizes machine learning and artificial intelli...
May 16, 2024
OmniAb Unveils Groundbreaking High-Throughput Single B-cell Screening Platform xPloration at the 20th Annual PEGS Boston Summit EMERYVILLE, Calif. - OmniAb, Inc. (Nasdaq: OABI), a pioneer in the biopharmaceutical industry, captivated attendees at the 20th Annual PEGS Boston - The Essential Protein and Antibody Engineering Summit, with a presentation of its sophisticated high-throughput single B-cell screening platform, xPloration. This year s summit, hosted at the Omni Hotel, provided a robust venue for OmniAb to showcase their innovation in antibody discovery and development. Revolutionizing Antibody Discovery with xPloration OmniAb s xPloration platform represents a monumental advancement in antibody disco...
Maxcyte Inc's business model revolves around providing cell engineering and flow electroporation technology to facilitate drug discovery, development, and manufacturing processes.
Regeneron Pharmaceuticals Inc operates a business model centered on the discovery and commercialization of cutting-edge biopharmaceuticals, particularly in the fields of ophthalmology, oncology, immunology, and rare diseases. They leverage their strong research and development capabilities, including their proprietary technologies, to create innovative therapies that address unmet medical needs. Additionally, Regeneron forms strategic collaborations and partnerships to enhance their development pipeline and expand market access for their products.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Ibio Inc is a plant-based biologics company that focuses on the development and manufacturing of therapeutic proteins. They utilize their proprietary plant-based expression system to produce biotherapeutics quickly and cost-effectively. By leveraging their platform, Ibio aims to address unmet medical needs and provide affordable and accessible treatments to patients worldwide.
Sources:
Omniab Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Omniab Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
